Treatment with pimodivir significantly decreased viral load over seven days versus placebo, in adult patients with acute, uncomplicated seasonal influenza A, according to results from the Phase 2b Topaz Trial by Janssen Pharmaceuticals.

Patients treated with pimodivir and oseltamivir (OST) also demonstrated a significantly lower viral load compared with those who received pimodivir alone at the same dose.

The primary endpoint data for the trial, presented in an oral presentation at the 5th International Society for Influenza and Respiratory Diseases Antiviral Group (ISIRV-AVG) Conference in Shanghai, China, showed treatment with pimodivir resulted in a statistically significant decrease in area under the curve (AUC) of viral load (by quantitative real-time-polymerase chain reaction [qRT-PCR]) over seven days from start of dosing, compared with placebo.

Differences in AUC are adjusted for baseline viral load and time from onset of influenza symptoms to the start of treatment (?24 hours or >24 to 48 hours).

Read more at www.pharmpro.com